1
|
Lam TC, Cho WCS, Au JSK, Ma ESK, Lam STS, Loong HHF, Wong JWH, Wong SM, Lee VHF, Leung RCY, Lau JKS, Kam MTY, Mok FST, Lim FMY, Nyaw JSF, Tin WWY, Cheung KM, Chan OSH, Kwong PWK, Cheung FY, Poon DM, Chik JYK, Lam MHC, Chan LWC, Wong SCC, Cao YB, Hui CV, Chen JZJ, Chang JH, Kong SFM, El Helali A. Consensus Statements on Precision Oncology in the China Greater Bay Area. JCO Precis Oncol 2023; 7:e2200649. [PMID: 37315266 PMCID: PMC10309548 DOI: 10.1200/po.22.00649] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 03/31/2023] [Accepted: 04/19/2023] [Indexed: 06/16/2023] Open
Abstract
BACKGROUND Next-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA. METHODS Thirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0. RESULTS The POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice. CONCLUSION POWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.
Collapse
Affiliation(s)
- Tai-Chung Lam
- Department of Clinical Oncology, Queen Mary Hospital/Hong Kong University-Shenzhen Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | | | - Joseph Siu-Kie Au
- Adventist Oncology Centre, Hong Kong Adventist Hospital, Hong Kong SAR, China
| | - Edmond Shiu-Kwan Ma
- Clinical and Molecular Pathology and Cancer Genetics Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China
| | - Stephen Tak-Sum Lam
- Clinical Genetic Service Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China
| | - Herbert Ho-Fung Loong
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Jason Wing Hon Wong
- School of Biomedical Sciences, The University of Hong Kong, Hong Kong SAR, China
| | - S.N. Michael Wong
- Department of Clinical Oncology, Queen Mary Hospital/Hong Kong University-Shenzhen Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Victor Ho-Fun Lee
- Department of Clinical Oncology, Queen Mary Hospital/Hong Kong University-Shenzhen Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | | | | | - Michael Tsz-Yeung Kam
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China
| | | | - Fiona Mei-Ying Lim
- Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong SAR, China
| | | | | | - Ka-Man Cheung
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China
| | | | | | - Foon-Yiu Cheung
- Hong Kong International Oncology Centre, Hong Kong SAR, China
| | - Darren M.C. Poon
- Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China
| | | | | | - Lawrence Wing-Chi Chan
- Department of Health Technology & Informatics, Hong Kong Polytechnic University, Hong Kong SAR, China
| | - Sze-Chuen Cesar Wong
- Department of Health Technology & Informatics, Hong Kong Polytechnic University, Hong Kong SAR, China
- Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong SAR, China
| | - Ya-Bing Cao
- Department of Radiology & Oncology, Kiang Wu Hospital, Macao SAR, China
| | - Cheng-Vai Hui
- Department of Clinical Oncology, Centro Hospitalar Conde de São Januário, Macao SAR, China
| | - Jack Zhi-Jian Chen
- Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China
| | - Jian-Hua Chang
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China
| | - Spring Feng-Ming Kong
- Department of Clinical Oncology, Queen Mary Hospital/Hong Kong University-Shenzhen Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Aya El Helali
- Department of Clinical Oncology, Queen Mary Hospital/Hong Kong University-Shenzhen Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| |
Collapse
|
2
|
Yang B, Yuan J, Poon DM, Geng H, Lam WW, Cheung KY, Yu SK. Assessment of planning target volume margins in 1.5 T magnetic resonance‐guided stereotactic body radiation therapy for localized prostate cancer. Precision Radiation Oncology 2022. [DOI: 10.1002/pro6.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Bin Yang
- Medical Physics Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Jing Yuan
- Research Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Darren M.C. Poon
- Comprehensive Oncology Centre Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Hui Geng
- Medical Physics Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Wai Wang Lam
- Medical Physics Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Kin Yin Cheung
- Medical Physics Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| | - Siu Ki Yu
- Medical Physics Department Hong Kong Sanatorium & Hospital Happy Valley Hong Kong China
| |
Collapse
|
3
|
Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, Dorff TB, Gleave M, James ND, Poon DM, Suzuki H, Sweeney CJ. First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. Eur Urol Oncol 2022; 5:377-387. [DOI: 10.1016/j.euo.2022.04.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 04/02/2022] [Accepted: 04/29/2022] [Indexed: 12/01/2022]
|
4
|
Wong OL, Poon DM, Kam MK, Lo GG, Fung WW, Man SY, Xue C, Yu SK, Cheung KY, Yuan J. 3D‐T2W‐TSE radiotherapy treatment planning MRI using compressed sensing acceleration for prostate cancer: Image quality and delineation value. Asia Pac J Clin Oncol 2022; 18:e369-e377. [DOI: 10.1111/ajco.13752] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 12/13/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Oi Lei Wong
- Research Department Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Darren M.C. Poon
- Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Miachael K.M. Kam
- Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Gladys G. Lo
- Department of Diagnostic and Interventional Radiology Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Winky W.K. Fung
- Department of Radiotherapy Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Shei Yee Man
- Department of Radiotherapy Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Cindy Xue
- Research Department Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Siu Ki Yu
- Medical Physics Department Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Kin Yin Cheung
- Medical Physics Department Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| | - Jing Yuan
- Research Department Hong Kong Sanatorium and Hospital Hong Kong Hong Kong SAR
| |
Collapse
|
5
|
Loong HH, Hong A, Ng AW, Lacambra MD, Chiu WK, Tse T, Poon DM, Tan T, Tong C, Yip J, Ngan RK, Kumta S, Wong K. Proceedings of the 3rd Chinese University of Hong Kong (CUHK) Sarcoma Masterclass, September 21, 2019. J Immunother Precis Oncol 2020; 3:96-98. [PMID: 36751529 PMCID: PMC9179402 DOI: 10.36401/jipo-20-x1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 02/27/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Herbert H. Loong
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR
| | - Angela Hong
- Central School, Faculty of Medicine & Health, University of Sydney, Australia
| | - Alex W.H. Ng
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, Hong Kong SAR
| | - Maribel D. Lacambra
- Department of Anatomical Pathology, The Chinese University of Hong Kong, Hong Kong SAR
| | - Wang-kei Chiu
- Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR
| | - Teresa Tse
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR
| | - Darren M.C. Poon
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR
| | - Teresa Tan
- Department of Surgery, Prince of Wales Hospital, Hong Kong SAR
| | - Cina Tong
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, Hong Kong SAR
| | | | - Roger K.C. Ngan
- Department of Clinical Oncology, The University of Hong Kong, Hong Kong SAR
| | - Shekhar Kumta
- Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR
| | - K.C. Wong
- Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR
| |
Collapse
|
6
|
Poon DM, Chan K, Chan T, Ng B, Siu SWK, Ng J, Johnson D, Lee KC. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factors (GCSF) in Chinese metastatic hormonal-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
72 Background: Plenty reports suggest Asian prostate cancer patients are more susceptible to docetaxel-related febrile neutropenia (FN). However, primary GCSF prophylaxis is currently not recommended by international guidelines for patients with mCRPC or mHSPC when docetaxel is administered. Therefore, we aim to evaluate the potential benefit of primary GCSF in preventing the potentially life-threatening FN for Chinese mHSPC and mCRPC treated with docetaxel. Methods: Two cohorts (2003-2012 & 2015-2018) that consisted of Chinese patients with mHSPC and mCRPC who had docetaxel at six public oncology centres in Hong Kong were grouped and analysed. Primary GCSF was defined as its administration within 5 days of beginning docetaxel, and its use was at the discretion of oncologists. The primary outcome was FN within 21 days of first cycle of docetaxel (1st FN). Multivariable regression analysis was used. Results: A total of 377 metastatic prostate cancer (mHSPC, n=100 (26%); mCRPC, n=277 (73%)) patients with docetaxel treatment was identified. Primary GCSF was given in 71 (18%) patients. The baseline characteristics were balanced between groups with and without primary GCSF. FN was happened in 61 patients (16%), with 37 (9%) of them at 1st cycle. Primary GCSF were administered in 2 and 69 patients with and without 1st FN, respectively (5.4% vs 20.3%, p=0.03). Primary GCSF was associated with reduced risk of 1st FN (odds ratio (OR), 0.22; 95% CI 0.05 - 0.96; p=0.04) in overall, and a similar trend was observed in both mHSPC (OR, 0.36; p=0.35) and mCRPC (OR, 0.16, p=0.08) subgroups. Besides, among various clinical parameters, poor performance status (ECOG 2-3) was associated with increased risk of 1st FN (OR, 3.90, 95% CI 1.66 – 9.13, p=0.002). Conclusions: Primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status, to alleviate the risk of docetaxel-related febrile neutropenia.
Collapse
Affiliation(s)
- Darren M.C. Poon
- State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
| | - Kuen Chan
- Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
| | - T.W. Chan
- Queen Elizabeth Hospital, Hong Kong, China
| | - Bryan Ng
- Department of Oncology, Princess Margaret Hospital Hong Kong, Hong Kong, China
| | | | - Joyce Ng
- State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
| | - David Johnson
- State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
| | - Ka Chai Lee
- Tuen Mun Hospital, Hong Kong, Tuen Mun, China
| | | |
Collapse
|
7
|
Ng W, Wong EC, Cheung AK, Chow JC, Poon DM, Lai JW, Chiang C, Choi HC, Chau T, Lee VH, Lee AW, Tam AH, Au K. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT—A study by the HKNPCSG. Head Neck 2019; 41:3661-3669. [PMID: 31350940 DOI: 10.1002/hed.25892] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 07/11/2019] [Accepted: 07/11/2019] [Indexed: 11/05/2022] Open
Affiliation(s)
- Wai‐Tong Ng
- Department of Clinical OncologyPamela Youde Nethersole Eastern Hospital Hong Kong China
| | - Edwin C.Y. Wong
- Department of Clinical OncologyPamela Youde Nethersole Eastern Hospital Hong Kong China
| | | | - James C.H. Chow
- Department of Clinical OncologyQueen Elizabeth Hospital Hong Kong China
| | - Darren M.C. Poon
- Department of Clinical OncologyPrince of Wales Hospital Hong Kong China
| | - Jessica W.Y. Lai
- Department of Clinical OncologyPrincess Margaret Hospital Hong Kong China
| | - Chi‐Leung Chiang
- Department of Clinical OncologyLi Ka Shing Faulty of Medicine, The University of Hong Kong Hong Kong China
| | - Horace C.W. Choi
- Department of Clinical OncologyLi Ka Shing Faulty of Medicine, The University of Hong Kong Hong Kong China
| | - Tin‐Ching Chau
- Department of Clinical OncologyLi Ka Shing Faulty of Medicine, The University of Hong Kong Hong Kong China
| | - Victor H.F. Lee
- Department of Clinical OncologyLi Ka Shing Faulty of Medicine, The University of Hong Kong Hong Kong China
| | - Anne W.M. Lee
- Department of Clinical OncologyLi Ka Shing Faulty of Medicine, The University of Hong Kong Hong Kong China
| | | | - Kwok‐Hung Au
- Department of Clinical OncologyQueen Elizabeth Hospital Hong Kong China
| |
Collapse
|
8
|
Poon DM, Lam D, Wong KC, Chu C, Mo F, Suen J, Ng CF, Chan ATC. Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
27 Background: It remains uncertain whether stereotactic body radiotherapy (SBRT) is superior to conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in the treatment of early-stage prostate cancer. Here we report the 1-year late toxicity results from this randomized phase II study comparing SBRT and CF-IMRT. Methods: The primary endpoint of this single centre randomized phase II study is the health-related quality of life (HRQOL), as measured by the bowel and urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument. The secondary endpoints include toxicities, biochemical control and overall survival. We enrolled low and intermediate risk localized prostate cancer patients (T1-T2, Gleason score ≤7 and PSA <20). Patients were randomly assigned in a 1:1 ratio to receive either CF-IMRT with 38 fractions of 2 Gy in 7.5 weeks (five fractions per week) or SBRT with 5 fractions of 7.25 Gy in 2 weeks (three fractions per week). Neoadjuvant androgen-deprivation treatment is optional for the intermediate risk patients. A 1-year late adverse event is defined as the first occurrence of worst severity of the adverse event within 1 year after the completion of RT, and it was evaluated with the Common Terminology Criteria for Adverse Events (version 4.0). Patient recruitment was completed in May 2017. Results: Between Jan 2015 and May 2017, 68 patients were recruited and 4 patients were not eligible. 64 patients were randomized to treatments with SBRT (n=31) or CF-IMRT (n=33). At 1- year follow-up, two grade 3 genitourinary (GU) late toxicities, one in each arm (3%), were reported. SBRT patients experienced significantly less ≥ grade 1 late gastrointestinal (GI) toxicities (SBRT vs IMRT: 64% vs 84%, p=0.041) and similar ≥grade 1 late GU toxicities (SBRT vs IMRT: 93% vs 100%, p=0.2307) to IMRT patients. Conclusions: SBRT results in significantly less 1-year late GI toxicities than CF-IMRT in with low and intermediate risk prostate cancer. The study is registered at ClinicalTrials.gov (NCT02339701). Clinical trial information: NCT02339701.
Collapse
Affiliation(s)
- Darren M.C. Poon
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
| | - Daisy Lam
- Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | | | - C.M Chu
- Department of Imaging and Interventional Radiology , Prince of Wales Hospital, Hong Kong, Hong Kong, Hong Kong
| | - Frankie Mo
- Sir YK Pao Center for Cancer, State Key Laboratory in Oncology in South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Joyce Suen
- Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong, Hong Kong
| | - Chi-Fai Ng
- Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Anthony T. C. Chan
- State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
9
|
Ai QY, King AD, Poon DM, Mo FK, Hui EP, Tong M, Ahuja AT, Ma BB, Chan AT. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncol 2019; 88:124-130. [DOI: 10.1016/j.oraloncology.2018.11.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 10/30/2018] [Accepted: 11/05/2018] [Indexed: 12/13/2022]
|
10
|
Poon DM, Wong KC, Chan T, Law K, Chan K, Lee KC, Lee C, Ting CF. The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.6_suppl.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
330 Background: The real-world data regarding the efficacy and toxicity, particularly fatigue, of Enzalutmide (Enza) as first and later line treatment options in mCRPC patients is currently lacking. We aimed to evaluate the survival outcome, PSA response and rate of fatigue of Enza in clinical practice outside trial setting. Methods: The clinical records of mCRPC patients treated with Enza from all 7 public oncology centers in Hong Kong between August 2015 and October 2017 were reviewed. The treatment efficacy and its determinants, and toxicities were determined. Results: A total of 117 mCRPC patients were treated with Enza, of whom 29.1%, 48.7%, 19.3% had Enza as their first (chemo-naïve), 2nd (post-docetaxel or abiraterone) and 3rd or above (had at least 2 of the prior followings: docetaxel, abiraterone, cabazitaxel or radium-223) line treatment options. Visceral metastases were present in 20.6/29.8/50% patients with 1st/ 2nd / 3rd or above line Enza. The median overall survival (OS) and progression-free survival (PFS) were not reached (1yr OS rate: 82%)/15.8/7.4 and 7.1/3.9/2.2 months for 1st/2nd/3rd or above lines Enza, respectively (p = 0.0002). PSA responses ( > 50% decline of PSA from baseline with Enza) were achieved in 73.5/35.1 (post-docetaxel: 53.8%/post-abiraterone: 29.5%)/19.2% patients with 1st/2nd/3rd or above lines Enza (p < 0.001). The presence of PSA response was associated with both favorable OS (HR 0.19; p < 0.0001) and PFS (HR 0.29; p < 0.001) in the multivariate analysis of whole cohort. Grade 1-2 and 3-4 fatigue was present in 44.1/59.6/57.7% and 5.9/7.0/19.2% patients with 1st/2nd/3rd or above line Enza, respectively (p = 0.023). The use of 3rd or above lines of Enza is significantly associated with grade 2 or above fatigue in multivariate analysis of whole cohort (HR = 8.05; p = 0.01). Conclusions: In real-world clinical setting, more frequent PSA response, longer OS and PFS was found in chemo-naïve patients with Enza. Patients with later lines of Enza had higher risk of fatigue.
Collapse
Affiliation(s)
- Darren M.C. Poon
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | | | - T.W. Chan
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - Kitty Law
- Princess Margaret Hospital, Hk, Hong Kong
| | - Kuen Chan
- Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
| | - Ka Chai Lee
- Tuen Mun Hospital, Hong Kong, Tuen Mun, Hong Kong
| | - Conrad Lee
- United Christian Hospital, Hong Kong, Hong Kong
| | | | | |
Collapse
|
11
|
Au K, Ngan RK, Ng AW, Poon DM, Ng W, Yuen K, Lee VH, Tung SY, Chan AT, Sze HC, Cheng AC, Lee AW, Kwong DL, Tam AH. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol 2018; 77:16-21. [DOI: 10.1016/j.oraloncology.2017.12.004] [Citation(s) in RCA: 106] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Revised: 11/26/2017] [Accepted: 12/07/2017] [Indexed: 12/09/2022]
|